Protagonist Therapeutics, Inc Net Income (Loss) Available to Common Stockholders, Basic
Protagonist Therapeutics, Inc (PTGX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$38.92 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-12.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2019-03-12
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for the quarter ending 2017-12-31 was -$3.05M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for the quarter ending 2017-09-30 was -$4.83M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for the quarter ending 2017-06-30 was -$14.98M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for the quarter ending 2017-03-31 was -$14.10M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for fiscal 2018 was -$38.92M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for fiscal 2017 was -$36.96M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for fiscal 2016 was -$37.73M.
- Protagonist Therapeutics, Inc net income (loss) available to common stockholders, basic for fiscal 2015 was -$14.93M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$38.92M 10-K · filed 2019-03-12 | |||
| 2017-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$7.88M derived: sum of 2 quarters · filed 2019-03-12 | -$22.86M derived: sum of 3 quarters · filed 2019-03-12 | -$36.96M 10-K · filed 2019-03-12 |
| 2017-09-30 | -$4.83M 10-Q · filed 2017-11-07 | -$19.80M derived: sum of 2 quarters · filed 2017-11-07 | -$33.91M 10-Q · filed 2017-11-07 | -$45.15M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$14.98M 10-Q · filed 2017-08-08 | -$29.08M 10-Q · filed 2017-08-08 | -$40.33M derived: sum of 3 quarters · filed 2019-03-12 | -$47.70M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$14.10M 10-Q · filed 2017-05-10 | -$25.35M derived: sum of 2 quarters · filed 2019-03-12 | -$32.73M derived: sum of 3 quarters · filed 2019-03-12 | -$40.05M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$11.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$18.63M derived: sum of 2 quarters · filed 2019-03-12 | -$25.95M derived: sum of 3 quarters · filed 2019-03-12 | -$37.73M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$7.38M 10-Q · filed 2017-11-07 | -$14.70M derived: sum of 2 quarters · filed 2017-11-07 | -$26.49M 10-Q · filed 2017-11-07 | -$32.02M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$7.32M 10-Q · filed 2017-08-08 | -$19.11M 10-Q · filed 2017-08-08 | -$24.64M derived: sum of 3 quarters · filed 2018-03-07 | -$28.13M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$11.79M 10-Q · filed 2017-05-10 | -$17.32M derived: sum of 2 quarters · filed 2018-03-07 | -$20.80M derived: sum of 3 quarters · filed 2018-03-07 | -$24.02M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$9.02M derived: sum of 2 quarters · filed 2018-03-07 | -$12.24M derived: sum of 3 quarters · filed 2018-03-07 | -$14.93M 10-K · filed 2018-03-07 |
| 2015-09-30 | -$3.48M 10-Q · filed 2016-11-14 | -$6.70M derived: sum of 2 quarters · filed 2016-11-14 | -$9.40M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$3.22M 10-Q · filed 2016-09-15 | -$5.92M 10-Q · filed 2016-09-15 | ||
| 2014-12-31 | -$11.22M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |